Swedbank AB Acquires Shares of 90,900 NewAmsterdam Pharma Company N.V. $NAMS

Swedbank AB acquired a new stake in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 90,900 shares of the company’s stock, valued at approximately $3,189,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in NAMS. Capital World Investors lifted its holdings in NewAmsterdam Pharma by 17.1% during the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock valued at $279,358,000 after purchasing an additional 1,434,986 shares in the last quarter. Jennison Associates LLC lifted its holdings in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after purchasing an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC lifted its holdings in NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock valued at $54,710,000 after purchasing an additional 1,091,525 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in NewAmsterdam Pharma by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after purchasing an additional 1,062,359 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in NewAmsterdam Pharma by 21.0% during the third quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock valued at $114,332,000 after purchasing an additional 697,129 shares in the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Michael H. Davidson sold 443,707 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer directly owned 174,144 shares in the company, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the sale, the insider owned 69,302 shares of the company’s stock, valued at approximately $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 1,168,286 shares of company stock worth $38,211,967 over the last three months. Insiders own 20.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on NAMS shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Tuesday, April 21st. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright upgraded shares of NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.00.

NewAmsterdam Pharma Stock Up 11.1%

Shares of NASDAQ NAMS opened at $38.73 on Friday. The firm has a 50-day simple moving average of $31.77 and a 200-day simple moving average of $34.24. The stock has a market capitalization of $4.45 billion, a price-to-earnings ratio of -21.64 and a beta of 0.02. NewAmsterdam Pharma Company N.V. has a 52 week low of $16.78 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The business had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 25.90%. As a group, equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.81 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.